Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
An update to the American Radium Society's appropriate use criteria of lower grade Gliomas: Integration of IDH inhibitors.
An update to the American Radium Society's appropriate use criteria of lower grade Gliomas: Integration of IDH inhibitors. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Tom, M. C., Nagpal, S., Palmer, J. D., Breen, W. G., Pollom, E. L., Lehrer, E. J., McGranahan, T. M., Shiue, K., Chundury, A., McClelland Iii, S., Saeed, H., Chang, E. L., Chiang, V. L., Wang, T. J., Knisely, J. P., Chao, S. T., Milano, M. T. 2024: 110640Abstract
The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.
View details for DOI 10.1016/j.radonc.2024.110640
View details for PubMedID 39557126